The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce.

  title={The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce.},
  author={Joaquim Bellmunt and Sylvie N{\'e}grier and Bernard Escudier and Ahmad Awada and M 1467 Aapro},
  journal={Critical reviews in oncology/hematology},
  volume={69 1},
Treatments currently recommended for metastatic renal cell cancer (mRCC) have not been evaluated specifically in elderly patients. Here we consider what may be learned by analysing according to age the efficacy and toxicity data from key phase III trials of the targeted agents sorafenib (Nexavar), sunitinib (Sutent), temsirolimus (Torisel), and bevacizumab (Avastin), and from a study of expanded access to sunitinib and sorafenib. This paper represents the first systematic review of the role of… CONTINUE READING
30 Citations
26 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 30 extracted citations


Publications referenced by this paper.
Showing 1-10 of 26 references

Efficacy and safety of first - line bevacizumab plus interferon - alpha 2 a in subgroups of patients with metastatic renal cell carcinoma

  • B Escudier, A Ravaud, A Bracarda
  • ASCO Annu Meet Proc
  • 2008

Overall survival with sunitinib versus interferon - alfa as first - line treatment of metastatic renal cell carcinoma

  • RA Figlin, TE Hutson, P Tomcak
  • J Clin Oncol
  • 2008

Randomized phase II trial of first line treatment with sorafenib versus IFN in patients with advanced renal cell carcinoma : final results

  • C Szczylik, T Demkow, M Staehler
  • Lancet
  • 2008

Sequential use of sorafenib and sunitinib in renal cancer : retrospective analysis in 90 patients

  • MP Sablin, L Bouaita, C Balleyguier
  • ASCO GU Meet Proc .
  • 2008

Similar Papers

Loading similar papers…